ABBV
AbbVie Inc
NYSE: ABBV · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$211.32
+3.64% today
Updated 2026-04-30
Market cap
$360.63B
P/E ratio
99.95
P/S ratio
5.90x
EPS (TTM)
$2.04
Dividend yield
—
52W range
$171 – $239
Volume
7.0M
AbbVie Inc (ABBV) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.21B | $15.64B | $17.44B | $18.38B | $18.79B | $19.96B | $22.86B | $25.64B | $28.22B | $32.75B | $33.27B | $45.80B | $56.20B | $58.05B | $54.32B | $56.33B | $61.16B |
| Revenue growth (YoY) | — | +10.0% | +11.5% | +5.4% | +2.2% | +6.2% | +14.5% | +12.2% | +10.1% | +16.1% | +1.6% | +37.7% | +22.7% | +3.3% | -6.4% | +3.7% | +8.6% |
| Cost of revenue | $4.06B | $4.29B | $4.64B | $4.51B | $4.58B | $4.43B | $4.50B | $5.83B | $7.04B | $7.72B | $7.44B | $15.39B | $17.45B | $17.41B | $20.41B | $16.90B | $18.20B |
| Gross profit | $10.16B | $11.35B | $12.80B | $13.87B | $14.21B | $15.53B | $18.36B | $19.80B | $21.18B | $25.04B | $25.83B | $30.42B | $38.75B | $40.64B | $33.90B | $39.43B | $42.96B |
| Gross margin | 71.5% | 72.5% | 73.4% | 75.5% | 75.6% | 77.8% | 80.3% | 77.2% | 75.0% | 76.4% | 77.6% | 66.4% | 69.0% | 70.0% | 62.4% | 70.0% | 70.2% |
| R&D | $1.71B | $2.81B | $3.29B | $3.07B | $3.19B | $3.65B | $4.43B | $4.58B | $5.33B | $10.75B | $6.79B | $7.75B | $8.05B | $6.51B | $7.67B | $12.79B | $9.10B |
| SG&A | $3.35B | $3.82B | $5.89B | $4.99B | $4.73B | $5.36B | $4.96B | $5.07B | $5.40B | $6.25B | $5.84B | $8.07B | $10.25B | $13.26B | $10.70B | $11.09B | $14.01B |
| Operating income | $4.93B | $4.72B | $3.62B | $5.82B | $5.66B | $3.41B | $7.54B | $9.34B | $9.54B | $6.38B | $12.98B | $11.36B | $17.92B | $18.12B | $12.76B | $9.14B | $20.09B |
| Operating margin | 34.7% | 30.2% | 20.8% | 31.6% | 30.1% | 17.1% | 33.0% | 36.4% | 33.8% | 19.5% | 39.0% | 24.8% | 31.9% | 31.2% | 23.5% | 16.2% | 32.8% |
| EBITDA | $5.80B | $6.02B | $4.94B | $6.98B | $6.53B | $3.58B | $8.20B | $10.12B | $10.38B | $8.31B | $12.23B | $12.32B | $23.93B | $24.17B | $17.17B | $14.91B | $17.63B |
| EBITDA margin | 40.8% | 38.5% | 28.3% | 38.0% | 34.7% | 18.0% | 35.9% | 39.5% | 36.8% | 25.4% | 36.8% | 26.9% | 42.6% | 41.6% | 31.6% | 26.5% | 28.8% |
| EBIT | $5.10B | $4.84B | $3.67B | $5.83B | $5.63B | $2.80B | $7.36B | $8.93B | $8.88B | $6.54B | $10.21B | $5.85B | $15.41B | $15.71B | $8.47B | $6.52B | $9.49B |
| Interest expense | $0.00 | $0.00 | $0.00 | $104.00M | $299.00M | $429.00M | $719.00M | $1.05B | $1.15B | $1.35B | $1.78B | $2.45B | $2.42B | $2.23B | $2.22B | $2.81B | $2.89B |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $4.64B | $4.18B | $3.43B | $5.28B | $4.13B | $1.77B | $5.14B | $5.95B | $5.31B | $5.69B | $7.88B | $4.62B | $11.54B | $11.84B | $4.86B | $4.28B | $4.23B |
| Net income growth (YoY) | — | -9.9% | -17.8% | +53.7% | -21.7% | -57.0% | +190.0% | +15.7% | -10.8% | +7.1% | +38.6% | -41.4% | +150.0% | +2.5% | -58.9% | -12.0% | -1.2% |
| Profit margin | 32.6% | 26.7% | 19.7% | 28.7% | 22.0% | 8.9% | 22.5% | 23.2% | 18.8% | 17.4% | 23.7% | 10.1% | 20.5% | 20.4% | 9.0% | 7.6% | 6.9% |